• renal
  • Although patients with and without prior exposure to microsomal enzyme-inducing drugs demonstrated marked variation in plasma cyclophosphamide half-life and peak alkylating levels, the total concentration × time product remained relatively constant for a given cyclophosphamide dose, suggesting that alterations in the rate of cyclophosphamide metabolism by drugs or liver metastases in the absence of renal failure will not change toxicity or therapeutic effect. (aacrjournals.org)
  • Wagner T, Heydrich D, Bartels H, Hohorst HJ (1980) The influence of damaged liver parenchyma, renal insufficiency and haemodialysis on the pharmacokinetic of cyclophosphamide and its activated metabolites. (springer.com)
  • remission
  • acute lymphoblastic (stem-cell) leukemia in children (cyclophosphamide given during remission is effective in prolonging its duration). (nih.gov)
  • In children whose disease fails to respond adequately to appropriate adrenocorticosteroid therapy or in whom the adrenocorticosteroid therapy produces or threatens to produce intolerable side effects, cyclophosphamide may induce a remission. (nih.gov)
  • dose
  • Adverse drug reactions from cyclophosphamide are related to the cumulative medication dose and include chemotherapy-induced nausea and vomiting, bone marrow suppression, stomach ache, hemorrhagic cystitis, diarrhea, darkening of the skin/nails, alopecia (hair loss) or thinning of hair, changes in color and texture of the hair and lethargy. (wikipedia.org)
  • Not more than 20% of injected cyclophosphamide was excreted intact in urine at any dose level. (aacrjournals.org)
  • drugs
  • Cyclophosphamide decreases the immune system's response, and although concerns about toxicity restrict its use to patients with severe disease, it remains an important treatment for life-threatening autoimmune diseases where disease-modifying antirheumatic drugs (DMARDs) have been ineffective. (wikipedia.org)
  • A list of drugs that interact with Cyclophosphamide. (evidence.nhs.uk)
  • liver
  • Cyclophosphamide is biotransformed principally in the liver to active alkylating metabolites by a mixed function microsomal oxidase system. (nih.gov)
  • It is concluded that severe liver disease has a significant effect on the disposition of cyclophosphamide, and that it could lead to accumulation of the drug in the body. (springer.com)
  • urine
  • Jardine I, Fenselau C, Appler M, Kan MN, Brundrett RB, Colvin M (1978) Quantitation by gas chromatography-chemical ionisation mass spectrometry of cyclophosphamide, phosphoramide mustard and nor-nitrogen mustard in plasma and urine of patients receiving cyclophosphamide therapy. (springer.com)
  • toxic
  • It has not been demonstrated that any single metabolite is responsible for either the therapeutic or toxic effects of cyclophosphamide. (nih.gov)